ArticleMedical mycology2026
Anti-cytokine autoantibodies in cryptococcal meningitis differ by HIV status: A cross-sectional analysis.
Article in Medical mycology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Neutralizing anti-cytokine autoantibodies (ACAAs) have been associated with cryptococcal meningitis (CM), but the influence of HIV co-infection remains undefined. We investigated plasma ACAA profiles and function in a cross-sectional Vietnamese cohort stratified by HIV and CM status (n = 20 per group). We quantified plasma ACAAs against interferons (IFNs), interleukins (ILs), and granulocyte-macrophage colony-stimulating factor (GM-CSF) using a particle-based assay, and assessed their neutralizing activity in high-titer samples. Associations between ACAA levels and CM were analyzed using Firth-penalized logistic regression, adjusting for age, sex, and CD4 count (in HIV-positive models). In HIV-negative individuals, higher anti-GM-CSF levels were associated with CM (odds ratio [OR] per log-unit increase, 1.84; 95% confidence interval [CI], 1.07-3.18). This association was predominantly observed in Cryptococcus gattii cases and was accompanied by functional neutralizing activity. Furthermore, adding pre-specified plasma IgG2 improved overall model fit and showed a strong inverse association with CM (OR, 0.03; 95% CI, 0.003-0.29). Conversely, HIV-positive CM cases had lower overall ACAA levels than non-CM controls. After adjusting for hypogammaglobulinemia/IgG1, significant inverse associations persisted for anti-IL-10, anti-IL-12, anti-IL-15, and anti-IL-22 with CM status. Type I IFN-binding ACAAs were largely non-neutralizing. These findings reveal distinct pathogenic mechanisms. In HIV-negative CM, neutralizing anti-GM-CSF antibodies, often in C. gattii infection, and low IgG2 were independently associated with disease. In HIV-positive CM, ACAA reductions without cytokine neutralization may reflect underlying antibody and/or B-cell deficiency. Longitudinal studies are needed to clarify the clinical implications of ACCAs, particularly in HIV-negative CM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.